Skip to main content
Premium Trial:

Request an Annual Quote

DxS and BTG to Market AstraZeneca s DNA Diagnostic Technology

NEW YORK, March 23 (GenomeWeb News) - DxS and BTG said today that they have signed an exclusive license to commercialize technology developed by AstraZeneca for the detection of SNPs and other gene mutations.

DxS and BTG said they had acquired "certain rights" to AstraZeneca's technology, and would market AstraZeneca's Amplification Refractory Mutation System (ARMS) within the diagnostic and research markets.

The technology will be targeted toward companies that offer genetic variation products and services, as well as companies that are already using ARMS as part of their in-house research activities, DxS and BTG said.

DxS, a genetic analysis services provider, will offer ARMS in addition to its own Scorpions genotyping system. Stephen Little, DxS CEO, called ARMS "an excellent fit with our current portfolio."

The Scan

Unique Germline Variants Found Among Black Prostate Cancer Patients

Through an exome sequencing study appearing in JCO Precision Oncology, researchers have found unique pathogenic or likely pathogenic variants within a cohort of Black prostate cancer patients.

Analysis of Endogenous Parvoviral Elements Found Within Animal Genomes

Researchers at PLOS Biology have examined the coevolution of endogenous parvoviral elements and animal genomes to gain insight into using the viruses as gene therapy vectors.

Saliva Testing Can Reveal Mosaic CNVs Important in Intellectual Disability

An Australian team has compared the yield of chromosomal microarray testing of both blood and saliva samples for syndromic intellectual disability in the European Journal of Human Genetics.

Octopus Brain Complexity Linked to MicroRNA Expansions

Investigators saw microRNA gene expansions coinciding with complex brains when they analyzed certain cephalopod transcriptomes, as they report in Science Advances.